#United States #San Francisco #Nektar Therapeutics #Immunology #Jefferies Conference

Nektar Therapeutics Set to Participate in the Jefferies Global Healthcare Conference 2025

Nektar Therapeutics, a prominent clinical-stage biopharmaceutical company, has announced its participation in the upcoming Jefferies Global Healthcare Conference, slated for November 17-20, 2025, in London. This event presents a significant platform for Nektar to showcase its advancements in biopharmaceuticals, particularly their innovative treatments aimed at chronic inflammatory and autoimmune diseases.

Webinar Details and Presentation Overview

The company's management will be hosting a live webcast during the conference, specifically on Thursday, November 20, 2025, scheduled for 11:00 AM GMT (3:00 AM PT). Interested participants can access the presentation through the webcast link provided on the Nektar website. For those unable to attend live, a replay will be made available for a period of 30 days following the presentation.

This year’s conference highlights the commitment of Nektar Therapeutics to engage with the broader healthcare community, sharing developments related to their investigational drugs and ongoing research projects. Attendees will have the opportunity to learn more about Nektar’s flagship product, rezpegaldesleukin (REZPEG), which acts as a regulatory T cell stimulator.

Nektar’s Pioneering Drug Candidates

Nektar Therapeutics is at the forefront of biotechnology, focusing on treatments that effectively address immunological dysfunctions. Their leading candidate, REZPEG or NKTR-358, is currently undergoing evaluation in various Phase 2b clinical trials designed to treat conditions such as atopic dermatitis and alopecia areata. Moreover, it is also being studied for its potential effectiveness in managing Type 1 diabetes mellitus.

The company’s portfolio is impressive, featuring several other innovative candidates in different stages of development. This includes a preclinical bivalent TNFR2 antibody, bispecific immunotherapies NKTR-0165 and NKTR-0166, and a modified CSF protein known as NKTR-422. Additionally, in collaboration with various partners, Nektar is investigating NKTR-255, an experimental IL-15 receptor agonist intended to enhance the body’s immune response against cancer.

Engaging with the Healthcare Community

The participation at the Jefferies Global Healthcare Conference underscores Nektar Therapeutics’ strategy to reach out to investors and potential collaborators who share its vision for pioneering treatment of chronic conditions. Stakeholders interested in a one-on-one meeting with Nektar’s management during the conference are encouraged to coordinate through their contact representatives at Jefferies.

Nektar Therapeutics is highly regarded for its innovative approach and tireless commitment to advancing biopharmaceutical solutions that can transform patient outcomes. The upcoming conference thus represents not only a pivotal moment for the company but also an exciting opportunity for the healthcare community to engage with new research and insights.

For further updates, stakeholders can visit Nektar’s official website or their LinkedIn page for information regarding their latest research and development initiatives.

Conclusion

As Nektar Therapeutics approaches the Jefferies Global Healthcare Conference in London, it is poised to reinforce its role as a leader in the biotechnology sector. The webcast and presentations from the conference are anticipated to shed light on the future pathways for the company’s groundbreaking treatments and the impact they aim to achieve in the realm of immunology and chronic disease management.